Insider buying last 90 days
No open-market insider purchases were filed for HAE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Haemonetics shares moved this week on second-quarter fiscal 2027 results and a raised outlook. The company reported organic revenue growth of 10% in the quarter and 8% in the first half, with adjusted EPS up 6% in both periods, and raised its fiscal 2027 revenue growth guidance while lowering its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL. Net revenue rose 9.3% to $357.8 million with net income up 19.7% to $46.3 million, and Mizuho raised its price target to $165 from $140 while maintaining an Outperform rating, citing 18% organic growth in plasma.
The stock closed at $118.21, down 1.4% on the day, and sits above both its 50-day average of $111.76 and its 200-day average of $80.16, with the 50-day above the 200-day. The GekkoIndex reads 55.5, placing it in the Neutral zone. Price is essentially in line with Gekko Fair Value of $118.07, a gap of 0.1%.
The next earnings date is 4 February 2027, 81 days away and outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days from this point in the calendar have averaged -1.1% over 5 years, rising in 3 of those years. Analyst sentiment stands at 7 buy and 1 hold among 8 firms, with a consensus target of $124.50.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Haemonetics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $122.94 is above the 50-day ($113.31) and 200-day ($81.26) averages, and the 50-day is above the 200-day.
See the chart54.1, Neutral
Reading 54.1 is in the Neutral zone.
See the GekkoIndex2.7% above
Price is within 5% of Gekko Fair Value (2.7% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 81 days
Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.
See earnings−1.5% on average
From this point in the calendar, the next 20 trading days averaged −1.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Haemonetics closed at $122.94 on Nov 13, 2026, +68.1% over the past year, inside a 52-week range of $51.00 to $132.00.
Use the left and right arrow keys to read daily values.
Put HAE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Haemonetics makes medical devices and software used in blood and plasma management. Its products range from automated plasma collection systems to blood component collection technology and hospital tools that measure how well a patient's blood clots, with the hemostasis analyzers and autologous blood recovery systems among its recognized offerings.
The business is organized around three areas: plasma, blood centers, and hospitals. In plasma, it supplies collection devices along with donor management and IT systems that help customers track donors and supply chains. Its blood center offerings include apheresis equipment for collecting blood components and software for managing blood bank operations and transfusions. On the hospital side, it provides clotting analysis systems paired with software that lets clinicians review test results across a facility, plus equipment for recovering a patient's own blood during surgery. Haemonetics reaches customers through its own sales staff as well as independent distributors and representatives.
The company was founded in 1971 and is headquartered in Boston, Massachusetts. Its shares are listed on the NYSE under the ticker HAE.
Haemonetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.1, in the Neutral zone, up 1.7 points over five sessions.
Up 1.7 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 89 | −0.6% | +1.6% |
| Accumulation | 220 | 0.0% | +2.2% |
| Neutral (current zone) | 299 | +1.0% | +2.5% |
| Distribution | 83 | +1.3% | +2.4% |
| Selling | 11 | −0.3% | +1.4% |
Average HAE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Haemonetics trades 2.7% above Gekko Fair Value of $119.69, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Haemonetics shares are worth, recalculated every trading day.
$119.69
Gekko Fair Value, Nov 14, 2026
2.7% above fair value · About fair value
At the end of Aug 2026 the price was 26.3% below the estimate.
No open-market insider purchases were filed for Haemonetics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for HAE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in HAE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Haemonetics has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold HAE.
Haemonetics reports on Feb 4, 2027, before the open (81 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 4, 2027
Expected before the open, 81 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.14 est $1.07 | — | +5.1% |
| May 7, 2026 | $1.29 est $1.27 | $346.4M est $336.8M | +4.7% |
| Feb 5, 2026 | $1.31 est $1.27 | $339.0M est $331.9M | −10.0% |
| Nov 6, 2025 | $1.27 est $1.12 | $327.3M est $329.8M | +34.8% |
| Aug 7, 2025 | $1.10 est $1.01 | $321.4M est $320.0M | −28.7% |
| May 8, 2025 | $1.24 est $1.22 | $330.6M est $312.5M | +6.1% |
| Feb 6, 2025 | $1.19 est $1.18 | $348.5M est $354.5M | −16.7% |
| Nov 7, 2024 | $1.12 est $1.09 | $345.5M est $342.7M | +11.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Haemonetics is $144.55, +17.6% from the last close, from 10 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 10 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Jefferies | $150 | +22.0% |
| Nov 9 | J.P. Morgan | $125 | +1.7% |
| Nov 6 | Citi | $149 | +21.2% |
| Nov 6 | Barrington | $145 | +17.9% |
| Nov 6 | Bank of America Securities | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Haemonetics averaged −1.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.7% | 2 of 5 |
| Next 10 trading days | −1.7% | 2 of 5 |
| Next 15 trading days | −1.0% | 2 of 5 |
| Next 20 trading days | −1.5% | 2 of 5 |
| Next 30 trading days | −3.3% | 1 of 5 |
For scale, HAE’s typical 20-trading-day move in either direction is about 6.8%.
Haemonetics’s market cap is $5.60B, with a P/E ratio of 54.3 and revenue of $1.38B over the last twelve months.
Coverage of Haemonetics this week reads positive: 3 positive, 1 neutral and 1 negative headlines.
Haemonetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Haemonetics’s market cap is $5.60B at the Nov 13, 2026 close of $122.94, with 45.54M shares outstanding. The shares trade on a P/E ratio of 54.3.
The consensus analyst 12-month price target for Haemonetics is $144.55, +17.6% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Haemonetics is about fair value: the Nov 13, 2026 close of $122.94 is 2.7% above Gekko Fair Value of $119.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Haemonetics is expected to report on Feb 4, 2027, before the market opens (81 days away). Analysts expect earnings of $1.26 per share on revenue of $357.8M. Haemonetics beat the earnings estimate in 8 of its last 8 reports, moving 14.7% on average across the report.
Haemonetics’s 52-week high is $132.00 and its 52-week low is $51.00; it closed at $122.94 on Nov 13, 2026, +68.1% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.